Literature DB >> 23340685

[Complex space-occupying lesion of the lesser pelvis].

C Schäcke1, A Panzner, A Kovács, M Simon, J Barkhausen.   

Abstract

Mesh：

Year:  2013        PMID： 23340685     DOI： 10.1007/s00117-012-2437-6

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


× No keyword cloud information.
  6 in total

1.  Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas.

Authors:  Bengt Sorbe; Birgit Johansson
Journal:  Int J Oncol       Date:  2008-05       Impact factor: 5.650

2.  [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors].

Authors:  L-C Horn; M Dallacker; K Bilek
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

3.  Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.

Authors:  Jeong-Yeol Park; Dae-Yeon Kim; Dae-Shik Suh; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-28       Impact factor: 4.553

4.  Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.

Authors:  Dimitrios Pectasides; Eirini Pectasides; George Papaxoinis; Nikolaos Xiros; Constantinos Sykiotis; Antonios Papachristodoulou; Nikolaos Tountas; John Panayiotides; Theofanis Economopoulos
Journal:  Gynecol Oncol       Date:  2008-07-07       Impact factor: 5.482

5.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

Authors:  N S Reed; C Mangioni; H Malmström; G Scarfone; A Poveda; S Pecorelli; S Tateo; M Franchi; J J Jobsen; C Coens; I Teodorovic; I Vergote; J B Vermorken
Journal:  Eur J Cancer       Date:  2008-04-02       Impact factor: 9.162

6.  Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

Authors:  Paul J Hoskins; Nhu Le; Susan Ellard; Ursula Lee; Lee Ann Martin; Kenneth D Swenerton; Anna V Tinker
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.